Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2024-12-03

FDA Approved: BOSULIF — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)

View source ↗

Summary

The FDA approved a supplemental application for BOSULIF (bosutinib) from Pfizer, updating the drug’s labeling. This indicates a change to the approved labeling …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • BOSULIF (bosutinib)

Snippet

SUPPL AP for BOSULIF (BOSUTINIB)